PDF(Pubmed)
Abstract：
OBJECTIVE: Since its first description, alpha-fetoprotein has become the most widely used marker for diagnosing and monitoring patients with hepatocellular carcinoma (HCC). This study aims to assess the correlation between serum levels of alpha-fetoprotein and tumour dimensions in patients diagnosed with HCC, that were previously treated with direct-acting antivirals for hepatitis C viral infection.
METHODS: We conducted a retrospective cohort study on 47 patients with a personal history of hepatitis C virus infection, who were diagnosed with different forms of HCC more than one year after achieving sustained virologic response after 12 weeks post-treatment. Patients were monitored by liver function tests, tumoral markers, blood cell count and coagulation profile and underwent imagistic explorations such as abdominal ultrasonography and, in selected cases, computerised tomography/magnetic resonance imaging. Tumour burden was assessed by both tumour burden score and seven-eleven criteria.
RESULTS: The study mostly included cirrhotic patients, multinodular HCC being the predominant pattern. All patients had alpha-fetoprotein levels over 100 ng/ml, with values largely varying, in accordance with the tumour dimensions. Most patients had medium-range Tumour Burden Score, a variable that also correlated with nodule size.
CONCLUSIONS: The study found a significant correlation between serum alpha-fetoprotein and tumour size in patients with HCC. Alpha-fetoprotein also correlated well with Tumour Burden Score and remains a very important diagnostic and prognostic tool for patients with HCC.
METHODS: We conducted a retrospective cohort study on 47 patients with a personal history of hepatitis C virus infection, who were diagnosed with different forms of HCC more than one year after achieving sustained virologic response after 12 weeks post-treatment. Patients were monitored by liver function tests, tumoral markers, blood cell count and coagulation profile and underwent imagistic explorations such as abdominal ultrasonography and, in selected cases, computerised tomography/magnetic resonance imaging. Tumour burden was assessed by both tumour burden score and seven-eleven criteria.
RESULTS: The study mostly included cirrhotic patients, multinodular HCC being the predominant pattern. All patients had alpha-fetoprotein levels over 100 ng/ml, with values largely varying, in accordance with the tumour dimensions. Most patients had medium-range Tumour Burden Score, a variable that also correlated with nodule size.
CONCLUSIONS: The study found a significant correlation between serum alpha-fetoprotein and tumour size in patients with HCC. Alpha-fetoprotein also correlated well with Tumour Burden Score and remains a very important diagnostic and prognostic tool for patients with HCC.
摘要：
目标：自从第一次描述以来，甲胎蛋白已成为诊断和监测肝细胞癌（HCC）患者最广泛使用的标志物。本研究旨在评估甲胎蛋白的血清水平和肿瘤大小之间的相关性诊断为肝癌。以前用直接抗病毒药物治疗丙型肝炎病毒感染。
方法：我们对47例有丙型肝炎病毒感染史的患者进行了一项回顾性队列研究，在治疗后12周实现持续病毒学应答超过一年后被诊断为不同形式的HCC。患者通过肝功能检查进行监测，肿瘤标志物,血细胞计数和凝血情况，并进行了影像学检查，如腹部超声检查，在选定的情况下，计算机断层扫描/磁共振成像。通过肿瘤负荷评分和7-11标准评估肿瘤负荷。
结果：该研究主要包括肝硬化患者，多结节性肝癌是主要的模式。所有患者的甲胎蛋白水平均超过100ng/ml，值变化很大，根据肿瘤的尺寸。大多数患者有中等范围的肿瘤负担评分，也与结节大小相关的变量。
结论：研究发现肝癌患者血清甲胎蛋白与肿瘤大小之间存在显著相关性。甲胎蛋白也与肿瘤负担评分相关，并且仍然是HCC患者非常重要的诊断和预后工具。
方法：我们对47例有丙型肝炎病毒感染史的患者进行了一项回顾性队列研究，在治疗后12周实现持续病毒学应答超过一年后被诊断为不同形式的HCC。患者通过肝功能检查进行监测，肿瘤标志物,血细胞计数和凝血情况，并进行了影像学检查，如腹部超声检查，在选定的情况下，计算机断层扫描/磁共振成像。通过肿瘤负荷评分和7-11标准评估肿瘤负荷。
结果：该研究主要包括肝硬化患者，多结节性肝癌是主要的模式。所有患者的甲胎蛋白水平均超过100ng/ml，值变化很大，根据肿瘤的尺寸。大多数患者有中等范围的肿瘤负担评分，也与结节大小相关的变量。
结论：研究发现肝癌患者血清甲胎蛋白与肿瘤大小之间存在显著相关性。甲胎蛋白也与肿瘤负担评分相关，并且仍然是HCC患者非常重要的诊断和预后工具。
